首页BEAM • BMV
add
Beam Therapeutics Inc
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
收入 | 747.00万 | 0.81% |
经营支出 | 1.11亿 | 18.24% |
净收入 | -1.09亿 | -10.74% |
净利润率 | -1462.78 | -9.85% |
每股收益 | -1.24 | -2.48% |
息税折旧摊销前利润 | -1.14亿 | -15.26% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 12.20亿 | 11.46% |
总资产 | 14.67亿 | 7.88% |
负债总额 | 3.44亿 | -22.97% |
权益总额 | 11.23亿 | — |
发行在外的股份 | 9748.62万 | — |
市净率 | 28.88 | — |
资产回报率 | -23.20% | — |
资本回报率 | -27.41% | — |
现金流
现金净变动
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
净收入 | -1.09亿 | -10.74% |
来自运营的现金 | -1.04亿 | -4.15% |
投资现金 | -1.25亿 | -133.97% |
融资现金 | 4.73亿 | 16,240.32% |
现金净变动 | 2.44亿 | 262.60% |
自由现金流 | -8592.28万 | -51.95% |
简介
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
CEO
成立时间
2017
员工数量
393
